newsfilter
← Latest News
ACCESS Newswire·

Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease

Application Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program